GCM
TAK icon

Gallacher Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Gallacher Capital Management’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$320K Sell
19,955
-4,565
-19% -$75.5K 0.18% 189
2026
Q1 		$454K Buy
24,520
+2,839
+13% +$49.8K 0.17% 169
2025
Q4 		$338K Sell
21,681
-5,564
-20% -$79.5K 0.13% 212
2025
Q3 		$399K Buy
27,245
+5,245
+24% +$77.9K 0.16% 203
2025
Q2 		$340K Buy
22,000
+2,507
+13% +$37K 0.16% 187
2025
Q1 		$290K Buy
19,493
+1,854
+11% +$26K 0.14% 196
2024
Q4 		$234K Buy
17,639
+415
+2% +$5.7K 0.12% 241
2024
Q3 		$245K Sell
17,224
-141
-0.8% -$2K 0.11% 235
2024
Q2 		$225K Buy
17,365
+1,136
+7% +$15K 0.12% 230
2024
Q1 		$225K Buy
16,229
+927
+6% +$13.5K 0.11% 227
2023
Q4 		$218K Sell
15,302
-148
-1% -$2.1K 0.12% 229
2023
Q3 		$239K Buy
15,450
+220
+1% +$3.41K 0.15% 189
2023
Q2 		$239K Buy
15,230
+1,205
+9% +$19.7K 0.14% 204
2023
Q1 		$231K Buy
14,025
+2,967
+27% +$47.3K 0.14% 202
2022
Q4 		$173K Buy
+11,058
New +$154K 0.1% 222

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Brandes Investment Partners
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Gallacher Capital Management's TAK Position: Q2 2026 in Review

Gallacher Capital Management reduced its Takeda Pharmaceutical (TAK) stake by 19% in Q2 2026, selling an estimated $75.5K and leaving 19,955 shares worth $320K. The position accounts for 0.18% of the portfolio, ranked #189.

Gallacher Capital Management first reported a position in TAK in Q4 2022 and has held it in 15 quarters since. The position peaked at $454K in Q1 2026. 379 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Gallacher Capital Management held 19,955 shares of Takeda Pharmaceutical worth $320K as of Q2 2026.
  • Gallacher Capital Management sold 4,565 Takeda Pharmaceutical shares in Q2 2026, an estimated $75.5K.
  • Takeda Pharmaceutical made up 0.18% of Gallacher Capital Management's portfolio in Q2 2026, its #189 holding.
  • Gallacher Capital Management first reported a position in Takeda Pharmaceutical in Q4 2022 and has held it in 15 quarters since.
  • Gallacher Capital Management's Takeda Pharmaceutical position peaked at $454K in Q1 2026.
  • 379 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Gallacher Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.